Results

Total Results: 1,528 records

Showing results for "drugs".

261. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/pelvic-pain_research-protocol.pdf
     February 16, 2011 - scientific evidence (level A) for using combined oral contraceptives and nonsteroidal anti-inflammatory drugs … Medical therapies • Analgesics o Non-narcotic agents including nonsteroidal anti-inflammatory drugs … Broad searches for grey literature and regulatory information on such commonly used drugs would likely … We consulted the TEP to determine which studies of drugs or devices would be likely to provide relevant … Our research team also thought it important to search for other drugs (e.g., aromatase inhibitors) that

262. Ch 5-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_5-user-guide-to-ocer_130129.pdf
     January 01, 2012 - However, the expected magnitude of confounding by BMI strongly depends on the specific drugs under … for patients treated with the oral dosage form mainly due to the different way of administering the drugs … For example, in a study assessing the risk of cancer in statin use,4 users of glaucoma drugs (like … However, because many treatments, particularly drugs, are approved for and/or clinically used to treat … Adherence to Drugs and Device Failure or Removal Patients who are on medications could have various

263. Methods Guide Atkins (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/methods_guide_atkins.pdf
     January 01, 2011 - For example, the individual trials of statin drugs to treat high cholesterol each selected specific … and discrete populations, used different drugs, different dosages, and different cointerventions. … differing risks, nationalities, and underlying conditions provides evidence that the benefits of statin drugs … Drugs 2007;67(14):1969-1979. 20. Walker, CF, Kordas K, Stoltzfus, RJ, et al. … Drug class review of Alzheimer’s drugs. Final report. 2006.

264. Research White Paper Multinational Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/multinational-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - focused on the outcomes, effectiveness, comparative clinical effectiveness, and appropriateness of pharmaceuticals … Food and Drug Administration [FDA], Health Canada, Japanese Pharmaceuticals and Medical Devices Agency … http://www.fda.gov/downloads/Drugs/Drug Safety/ucm089809.pdf. Accessed January 10, 2017. 21. … http://www.fda.gov/downloads/Drugs/Guida nces/ucm073122.pdf. Accessed January 10, 2017. 37. … /downloads/Drugs/DrugSafety/ucm089809.pdf http://www.wma.net/en/30publications/10policies/b3/ http://

265. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - Given the extensive detail on harms for these drugs, we were unable to summarize in a row and have … rather than redoing the entire meta-analysis, we chose to do focused meta- analyses just on those drugs … discussion: “In addition, larger, higher-quality studies have almost all been conducted with new drugs … with pharmaceutical company funding, and these were the only drugs with moderate strength of evidence … treatments improved quality of life, studies were short-term with unclear risk of bias, all oral drugs

266. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - Given the extensive detail on harms for these drugs, we were unable to summarize in a row and have … rather than redoing the entire meta-analysis, we chose to do focused meta- analyses just on those drugs … discussion: “In addition, larger, higher-quality studies have almost all been conducted with new drugs … with pharmaceutical company funding, and these were the only drugs with moderate strength of evidence … treatments improved quality of life, studies were short-term with unclear risk of bias, all oral drugs

267. CER 218 Evidence Summary: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-fracture-prevention-evidence-summary.pdf
     April 01, 2019 - observational studies presumed participants had osteoporosis because of past fracture or use of osteoporosis drugs … Food and Drug Administration (FDA) approved osteoporosis drugs, including risedronate, ibandronate, … Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti‐Resorptive Drugs

268. Noninvasive Treatments for Low Back Pain: A Summary of the Research for Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/back-pain-treatment_consumer.pdf
     November 01, 2016 - Pain Type of Medicine About the medicine: Researchers found: NSAIDs (nonsteroidal anti- inflammatory drugs … Type of Medicine About the medicine: Researchers found: NSAIDs (nonsteroidal anti- inflammatory drugs … Possible Side Effects NSAIDs (nonsteroidal anti-inflammatory drugs) – Celecoxib (Celebrex®), diclofenac

269. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
     September 29, 2014 - decade ago the FDA established a 12-week duration of observation as a requirement for approval of drugs … behavior in persons with a legitimate (if not always appropriate) need to use the opioid class of drugs … opioid drug abuse and misuse, while simultaneously enabling appropriate access to pain-relieving drugs … Without considering how opioids should be used in the context of other drugs, devices or techniques, … in its class. ii Methadone’s unique properties distinguish it from other opioid drugs.

270. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1406.pdf
     January 01, 2020 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Along with access to relatively inexpensive illicit opioid drugs, such as heroin, and increased use … Available: http://www.accessdata.fda.gov/scripts/cder/drugs atfda/index.cfm? … For drugs that save lives, a steep cost. [internet].

271. What do we know about how evidence of harm and benefit is communicated in other countries? (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_international_king.ppt
     January 01, 2005 - Methods Literature Review Medline--1996-2006 Search Terms: Patient Education Evidence-based Medicine Pharmaceutical … Preparations Consumer Information Products from Other Countries Description Compare characteristics

272. MS Protocol draft_12_12-13 clean[2] (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/multiple-sclerosis_research-protocol.pdf
     December 17, 2013 - Thus, major questions of interest are whether or not disease-modifying MS drugs alter the natural history … evidence for patient values, beliefs, and preferences regarding discontinuation of disease- modifying drugs … KQ2: What are individual values, beliefs, and preferences regarding discontinuing disease-modifying drugs … Since these drugs are intended for long-term use, possibly for decades, we are looking for studies that … FDA-approved disease modifying drugs were only available after 1993.

273. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1312.pdf
     January 01, 2016 - San Diego (CA): Amylin Pharmaceuticals, Inc.; 2010 Jun 15 [accessed 2011 Feb 22]. [3 p]. … Amylin Pharmaceuticals. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2012 Feb 20]. [4 p]. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27. 11 p. … Get drugs straight to the eye. [internet].

274. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1412.pdf
     January 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Results The table below lists the four topics for which (1) preliminary phase III data for drugs, at … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2014 Apr 10]. [5 p]. … Get drugs straight to the eye. [internet].

275. Alcohol-Misuse-Drug-Therapy Consumer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_consumer.pdf
     February 01, 2016 - Medicines To Treat Alcohol Use Disorder A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: � Your doctor* said you have alcohol use disorder and need to stop drinking or cut down the amount you drink. � You have decided to stop or cut down your dri…

276. Alcohol-Misuse-Drug-Therapy Clinician (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_clinician.pdf
     February 01, 2016 - Pharmacotherapy for Adults With Alcohol Use Disorder (AUD) in Outpatient Settings Focus of This Summary This is a summary of a systematic review evaluating the evidence regarding the efficacy, comparative effectiveness, and adverse effects of medications in adults with alcohol use disorder (AUD). The systematic revi…

277. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … The topic, buprenorphine implant (Probuphine™, Titan Pharmaceuticals, Inc., South San Francisco, CA

278. Comparative Effectiveness Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Pharmacokinetics, Indications and Dosing of Included Drugs Drug and Trade Name (Trade names … provided only for drugs under patent.) … incapaciation and definite hazard to patient's health; adverse events defined according to Compendium of Pharmaceuticals … having a therapeutic effecton the knee joint) no yes Dolorgiet Pharmaceuticals (Germany … Pharmacokinetics, Indications and Dosing of Included Drugs Appendix B.

279. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Results The table below lists the four topics for which (1) preliminary phase III data for drugs or … interventions in this Executive Summary and report is organized alphabetically by device and then, pharmaceuticals … phentermine- topiramate (Qsymia®, Vivus, Inc., Mountain View, CA) and lorcaserin (Belviq®, Arena Pharmaceuticals

280. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results The table below lists the five topics for which (1) preliminary phase III data for drugs, at … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2014 Apr 10]. [5 p]. … Med Lett Drugs Ther. 2013 Dec 9;55(1431):97-8. PMID: 24322663. 74. … Drugs. 2013 Feb;73(2):187-93. PMID: 23335133.